{"id":535471,"date":"2021-09-08T08:04:15","date_gmt":"2021-09-08T12:04:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-08T08:04:15","modified_gmt":"2021-09-08T12:04:15","slug":"equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"

<\/p>\n

Equillium to Present at the H.C. Wainwright 23rd<\/sup> Annual Global Investment Conference<\/b><\/p>\n

LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–
\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd<\/sup> Annual Global Investment Conference, taking place September 13 \u2013 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET.\n<\/p>\n

\nBruce Steel, Equillium\u2019s chief executive officer, and Dolca Thomas M.D., Equillium\u2019s executive vice president of research and development and chief medical officer, will provide a high-level overview of itolizumab\u2019s mechanism of action and review each of the ongoing clinical programs. The presentation will focus on topline data from the company\u2019s Phase 1b EQUATE study in acute graft-versus-host disease (aGVHD) and recent regulatory feedback leading directly to a pivotal Phase 3 study in aGVHD, to be initiated before the end of 2021. Mr. Steel and Dr. Thomas will be available for one-on-one meetings during the conference.\n<\/p>\n

\nThe webcast will be available for 90 days under the \u201cInvestors\u201d section of the Company\u2019s website at https:\/\/ir.equilliumbio.com\/events-and-presentations<\/a>.\n<\/p>\n

About Equillium<\/b><\/p>\n

\nEquillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus\/lupus nephritis and uncontrolled asthma.\n<\/p>\n

\nFor more information, visit www.equilliumbio.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210908005387\/en\/<\/a><\/span><\/p>\n

Investor Contact
\n<\/b>
Michael Moore
\n
Vice President, Investor Relations & Corporate Communications
\n
619-302-4431
\n
ir@equilliumbio.com<\/a><\/p>\n

Media Contacts
\n<\/b>
Aljanae Reynolds
\n
Wheelhouse Life Science Advisors
\n
areynolds@wheelhouselsa.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Infectious Diseases Health Pharmaceutical Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference LA JOLLA, Calif.–(BUSINESS WIRE)– Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13 \u2013 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET. Bruce Steel, Equillium\u2019s chief executive officer, and Dolca Thomas M.D., Equillium\u2019s executive vice president of research and development and chief medical officer, will provide a high-level overview of itolizumab\u2019s mechanism of action and review each of the ongoing clinical programs. The presentation will … <\/p>\n

Continue reading “Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535471","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEquillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference LA JOLLA, Calif.–(BUSINESS WIRE)– Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13 \u2013 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET. Bruce Steel, Equillium\u2019s chief executive officer, and Dolca Thomas M.D., Equillium\u2019s executive vice president of research and development and chief medical officer, will provide a high-level overview of itolizumab\u2019s mechanism of action and review each of the ongoing clinical programs. The presentation will … Continue reading "Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:04:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-08T12:04:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":320,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-09-08T12:04:15+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference LA JOLLA, Calif.–(BUSINESS WIRE)– Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference, taking place September 13 \u2013 15, 2021. The virtual on-demand presentation will be available as of Monday, September 13, 2021, at 7:00 am ET. Bruce Steel, Equillium\u2019s chief executive officer, and Dolca Thomas M.D., Equillium\u2019s executive vice president of research and development and chief medical officer, will provide a high-level overview of itolizumab\u2019s mechanism of action and review each of the ongoing clinical programs. The presentation will … Continue reading \"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:04:15+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-08T12:04:15+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":320,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-09-08T12:04:15+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210908005387r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/equillium-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Equillium to Present at the H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535471"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535471\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535471"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535471"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}